OncoMatch/Clinical Trials/NCT03263572
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Is NCT03263572 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Blinatumomab and Cytarabine for accelerated phase chronic myelogenous leukemia, bcr-abl1 positive.
Treatment: Blinatumomab · Cytarabine · Methotrexate · Ponatinib — This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab, methotrexate, cytarabine, and ponatinib may work better in treating patients with acute lymphoblastic leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: ABL1 fusion
Required: BCR fusion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: investigational antileukemic agents or chemotherapy agents
Exception: unless full recovery from side effects has occurred or participant has rapidly progressive disease judged to be life-threatening by the investigator
Lab requirements
Liver function
Total serum bilirubin ≤ 2 x ULN (unless due to Gilbert's syndrome); ALT ≤ 3 x ULN; AST ≤ 3 x ULN
Cardiac function
Adequate cardiac function as assessed clinically by history and physical examination
Adequate liver function as defined by the following criteria ... Adequate cardiac function as assessed clinically by history and physical examination
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03263572 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational antileukemic agents or chemotherapy agents disqualifies patients from enrollment.
Does this trial require ABL1?
Yes, ABL1 fusion is a required biomarker for enrollment.
Does this trial require BCR?
Yes, BCR fusion is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify